HKSE · 2189.HK
Kato (Hong Kong) Holdings Limited
HK$0.50+HK$0.02 (+3.09%)
Kato (Hong Kong) Holdings Limited’s quoted price sits in the upper half of its reported 52-week range, 7.41% below the high.
Loading market information…
HKSE · 2297.HK · HKD
Stock price, earnings
Quote as of Oct 30, 2026, 07:58 AM UTC. Cached market data; not a live quote.
One-year closing-price history · HKD. Historical prices are not a forecast.
Rainmed Medical Limited’s quoted price sits in the lower half of its reported 52-week range, 50.0% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow Rainmed Medical Limited’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Rainmed Medical Limited is a medical technology firm specializing in the creation, development, and market launch of advanced systems that utilize coronary angiography to assess fractional flow reserve (FFR) and the index of microvascular resistance (IMR). Its offerings include the FlashAngio caFFR System, which accurately determines FFR values by reconstructing a three-dimensional model of the coronary arterial system from two angiographic images. Additionally, the company provides the FlashAngio caIMR System, an innovative non-invasive solution for the diagnosis and treatment of microcirculatory lesions. Rainmed Medical is also engaged in pioneering intelligent angiographic injection technologies, robotic navigation systems for vascular interventions, and flash renal denervation solutions. Established in 2014, the company is headquartered in Suzhou, China.
Latest available per-share figures in HKD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 08:46 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
HK$0.50+HK$0.02 (+3.09%)
Kato (Hong Kong) Holdings Limited’s quoted price sits in the upper half of its reported 52-week range, 7.41% below the high.
HK$0.71+HK$0.03 (+3.65%)
Vincent Medical Holdings Limited’s quoted price sits in the lower half of its reported 52-week range, 34.86% below the high.
HK$0.07HK$0.00 (0.0%)
Beijing Health (Holdings) Limited’s quoted price sits in the upper half of its reported 52-week range, 16.85% below the high.
HK$0.26HK$0.00 (0.0%)
China Health Group Limited’s quoted price sits in the lower half of its reported 52-week range, 69.77% below the high.
HK$0.37HK$0.00 (0.0%)
UMP Healthcare Holdings Limited’s quoted price sits in the lower half of its reported 52-week range, 27.0% below the high.
HK$0.52-HK$0.01 (-0.95%)
Austar Lifesciences Limited’s quoted price sits in the lower half of its reported 52-week range, 59.06% below the high.
HK$0.25-HK$0.02 (-7.55%)
China NT Pharma Group Company Limited’s quoted price sits in the lower half of its reported 52-week range, 75.5% below the high.
HK$1.46-HK$0.07 (-4.58%)
Qinghai Biotech Pharmaceutical Group Limited’s quoted price sits in the lower half of its reported 52-week range, 86.67% below the high.
